Your Eval Log Is the Trust Artifact
Demonstrating oversight, not claiming it.
Confidence: hypothesis. The failure modes below are drawn from published inspection findings and widely reported industry patterns, not firsthand deployment. The buildable pattern at the end is not lived: it is an unbuilt design. Argue with it.
You ship an eval suite. It passes. You tell your VP the system is safe. Six months later something breaks in production, and the first question isn't “what happened” — it's “how would we have known sooner.” If the honest answer is “we ran the eval suite once, before launch, and haven't touched it since,” you don't have a safety story. You have a screenshot.
As per my knowledge of one of the most heavily audited document cultures on earth — clinical drug development — a regulator's inspector can sit down in a conference room and ask an organization to produce, on the spot, the complete history of a decision made three years ago. That world figured out something AI teams are still learning: a claim of diligence is worthless. A log of diligence is the only thing anyone believes.
The clinical why: an inspection is an exam you've been taking all along
A quick gloss, since the vocabulary is unfamiliar if you've never worked in this world. A sponsor is the company running a clinical trial. GCP (Good Clinical Practice) is the international rulebook for how trials must be run and documented. The TMF (Trial Master File) is the repository meant to hold the trial's entire story — every version, deviation, and decision, with who made it and when. A CAPA (Corrective and Preventive Action) is the formal written response to a finding, promising what will change and by when.
Periodically — before approval, on routine schedule, or for cause — a regulatory inspector shows up and starts asking questions. Show me the delegation log. Show me this patient's dose change and everything around it. Show me how this problem was found, escalated, and fixed.
Here's the property that generalizes past clinical trials entirely: the inspector isn't just checking whether one event happened correctly. Underneath every specific question sits a meta-question — does this organization supervise itself? An inspector who finds one sloppy record starts wondering how many more exist unfound. An inspector who finds a sloppy record that the organization already knew about, investigated, and fixed draws the opposite conclusion: this organization catches its own mistakes.
This pattern is one piece of a longer treatment. The full essay is issue 33 of Stage × AI, a series walking the entire clinical-trial lifecycle stage by stage — what each stage really does, where AI helps, where it must not go, and one buildable pattern per stage:
full essayEvidence in, evidence out. Corrections welcome.